Securities code: 601607 securities abbreviation: Shanghai Pharmaceuticals Holding Co.Ltd(601607) No.: pro 2022-008 Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Suggestive announcement on the independent exercise mode adopted in the first exercise period of the A-share stock option incentive plan in 2019
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
According to the authorization of Shanghai Pharmaceuticals Holding Co.Ltd(601607) (hereinafter referred to as ” Shanghai Pharmaceuticals Holding Co.Ltd(601607) ” or “the company”) 2019 first extraordinary general meeting, 2019 second A-share class general meeting and 2019 second H-share class general meeting, the company held the 28th meeting of the seventh board of directors on January 5, 2022, The proposal on the achievement of exercise conditions in the first exercise period of 2019 A-share stock option incentive plan was reviewed and passed. For details, see the company’s website on Shanghai Stock Exchange on January 6, 2022（ http://www.sse.com.cn./ ）Announcement of Shanghai Pharmaceuticals Holding Co.Ltd(601607) on the achievement of exercise conditions in the first exercise period of 2019 A-share stock option incentive plan (Announcement No.: 2022-004). The first exercise period of the company’s 2019 A-share stock option incentive plan adopts the independent exercise mode. The main arrangements are as follows:
1. Number of exercises: 7667220
2. Number of exercisers: 190
3. Exercise price: 18.41 yuan / a share
4. Exercise method: independent exercise. The company has hired Haitong Securities Company Limited(600837) as the sponsor broker of independent exercise.
5. Stock source: RMB common shares (A shares) issued by the company to the incentive objects
6. Exercise arrangement: the exercise period is from February 14, 2022 to February 13, 2023. The shares obtained from exercise can be listed and traded on the second trading day (T + 2) after the exercise day (t day). The board of directors of the company shall determine the exercisable date according to the exercise window period specified in the policy, and apply for independent exercise for the incentive object according to relevant regulations. The incentive object shall choose to exercise the right independently within the exercisable period (except for the legally prohibited exercise period).
7. List of exercise objects and exercise conditions:
Name and position: the first feasible weight accounts for the total shares of equity incentive at the time of grant
Proportion of total quantity (share)
Zuo min executive director and President 158400 0.56% 0.006%
Li Yongzhong executive director and vice president 128700 0.45% 0.005%
Shen Bo, executive director, vice president, 128700 0.45% 0.005%
Chief financial officer
Zhao Yong, vice president 108900 0.38% 0.004%
Mao Jianyi, vice president 108900 0.38% 0.004%
Gu Haoliang, vice president 108900 0.38% 0.004%
Zhang Yaohua, vice president 108900 0.38% 0.004%
Chen Jinzhu, vice president and Secretary of the board of directors 108900 0.38% 0.004%
Middle managers and core backbone of the company 6706920 23.60% 0.236%
(182 persons in total)
Total 7667220 26.98% 0.270%
Note: if there is any difference in the mantissa between the sum of some total numbers and each detailed number in the above table, it is caused by the rounding of the percentage result; Note: for the first exercise period listed in the above table, the exercisable amount shall be subject to the actual amount confirmed by China Securities Depository and Clearing Co., Ltd.
8. According to the Shanghai Pharmaceuticals Holding Co.Ltd(601607) 2019 stock option incentive plan (Draft), the vesting date must be the trading day and shall not be the following inter district days:
(1) Within 30 days before the announcement of the company’s periodic report, if the announcement date of the periodic report is delayed due to special reasons, it shall be calculated from 30 days before the original scheduled announcement date to 1 day before the announcement;
(2) Within 10 days before the announcement of the company’s performance forecast and performance express;
(3) From the date of major events that may have a great impact on the trading price of the company’s shares and their derivatives or the date of entering the decision-making process to 2 trading days after disclosure according to law;
(4) Other periods prescribed by the CSRC and the stock exchange.
“Major transactions”, “major events” and “major events that may affect the stock price” are transactions or other major events that the company should disclose in accordance with the provisions of the stock listing rules of Shanghai Stock Exchange.
9. The company will disclose the quarterly changes of equity incentive objects, the adjustment of important parameters of stock options, the independent exercise of incentive objects and the changes of shares of the company in the form of regular reports or interim reports. It is hereby announced.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) board of directors
February 9, 2022
